Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Controlled, Single Center Clinical Trial to Evaluate the Efficacy and Safety of Neoadjuvant Therapy With Androgen Deprivation Therapy Combined With Docetaxel for High Risk and Very High Risk Prostate Cancer

NCT04869371 is registered in ClinicalTrials.gov with Hongqian Guo as lead sponsor.

NCT NCT04869371
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04869371 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Controlled, Single Center Clinical Trial to Evaluate the Efficacy and Safety of Neoadjuvant Therapy With Androgen Deprivation Therapy Combined With Docetaxel for High Risk and Very High Risk Prostate Cancer
Lead sponsor
Hongqian Guo
Phase
Phase 2
Overall status
Unknown status
Start date
December 12, 2018
Completion date
January 1, 2023
Enrollment
75 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neoadjuvant therapy \ high risk prostate cancer \ docetaxel